O(PE 9001 1 2 2007 July 10-15-07

Im

Date October 12, 2007

1696

TRADEMARE. PTO/SB/21 (10-07) Approved for use through 10/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/068.664 TRANSMITTAL Filing Date 02/06/2002 **FORM** First Named Inventor Chuan LI Art Unit 1636 **Examiner Name** James S. Ketter (to be used for all correspondence after initial filing) Attorney Docket Number N/A Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences ~ Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final **Proprietary Information Provisional Application** Power of Attorney, Revocation Affidavits/declaration(s) Change of Correspondence Address Status Letter Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below): Request for Refund **Express Abandonment Request** CD, Number of CD(s)_ Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) A petition to the Commissioner from requirement for restriction is included. Three pages of Reply to Missing Parts/ petition are separately numbered. Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name N/A Signature minn Printed name Chuan Li Date Reg. No. October 12, 2007 N/A CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Chuan Li

Typed or printed name



Amendments and request for reconsideration from requirement for restriction to application: DE NOVO SYNTHESIZED PLASMID, METHODS OF MAKING AND

USE THEREOF

Applicant Name: Chuan Li

Date: October 12, 2007

Application/Control Number: 10/068,664

Art Unit: 1636

a.) Introductory Comments

These are amendments and request for reconsideration from requirement for restriction to application (Application Number: 10/068,664) filed on February 6, 2002.

In claim 36, the phrase "SEQ ID NO: 41" is changed to "SEQ ID NO: 35".

The applicant disagrees with the requirement for restriction and request for reconsideration of the plasmids presented in the claims 26 to 40 to be examined in one group as a single invention.

The plasmids presented in claims 26 to 40 are synthesized by same design. The design was schematically illustrated in Fig. 1 of the application. As a matter of fact, all plasmids presented in the application were synthesized by this design and they were synthesized simultaneously in the same series of experiments.

In addition, these plasmids are functionally related. All claimed plasmids are based on pACYC replication origin which gives low copy number. Unexpected results of high copy number are observed with claimed plasmids. This functional property is useful because the protein expression in high copy number plasmids is higher than the expression in low copy number plasmids. High copy number plasmids are also useful in plasmid DNA production. Furthermore, the claimed plasmids appear to confer higher antibiotic resistance capacity for the host cells. Therefore the claimed plasmids are clearly functionally related.

Therefore the applicant presented evidences on the record that the presented plasmids are structurally and functionally related and respectfully requests that the petition for the plasmids presented in the claims 26 to 40 to be examined in one group as a single invention is granted.